Volume 16, Number 6 (Nov/Dec 2025)

Within this issue, read about a quality improvement project that improved the appropriate prescribing rate of olanzapine for chemotherapy-induced nausea and vomiting. Advanced practice providers (APPs) play a key role in detecting and managing adverse events in clinical practice, and this issue’s integrative review examines their role in early-phase oncology clinical trials. Learn about optimizing the dosing of regorafenib in patients with metastatic colorectal cancer, and gain insights on the long-term safety of lorlatinib for ALK-positive metastatic non-small cell lung cancer through an illustrative case study.

The development of a blood factor product formulary helped maximize patient outcomes and minimize adverse events at a large health system, as described in a Practice Matters article. In another cancer center, a formal career pathway program provided a structured pathway for the promotion and continuous career development of APPs.

Finally, read the first-hand accounts of clinical pharmacists as they describe their role in patient education and medication management, and explore ways for radiation oncology APPs to get involved in research.

We would like to thank the 65 peer reviewers who reviewed manuscripts for JADPRO this year.